Skip to content

Effects of intra-venous lidocaine in general anesthesia on postoperative inflammatory response and prognosis in patients with breast cancer

Effects of intra-venous lidocaine in general anesthesia on postoperative inflammatory response and prognosis in patients with breast cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039296
Enrollment
Unknown
Registered
2020-10-22
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Lidocaine Group:Total intravenous anesthesia was used. Lidocaine was used in the induction and maintenance of anesthesia
Opioids Group:Total intravenous anesthesia was used. Opioids was used in the induction and maintenance of anesthesia

Sponsors

Tongji Hospital Affiliated to Tongji University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Women who voluntarily participated in the study and whose age was >= 18 years old and <= 65 years old at the time of signing the informed consent; 2. Patients with primary breast cancer (T2-3, N0-2, M0); 3. Patients who plan to undergo unilateral radical mastectomy under general anesthesia; 4. American Society of anesthesiologists (ASA) grades I to III.

Exclusion criteria

Exclusion criteria: 1. Patients with inflammatory or metastatic breast cancer; 2. Patients who have received breast surgery; 3. Pregnant women; 4. Patients with severe diseases of heart, lung, liver, kidney and immune system 5. Patients with history of alcohol, sedatives or opioids addiction; 6. Patients allergic to lidocaine or any general anesthesia drugs; 7. Patients receiving preoperative radiotherapy or chemotherapy; 8. The patient can not cooperate with the study for any reason or other circumstances that the researcher thinks are not suitable for inclusion in this trial.

Design outcomes

Primary

MeasureTime frame
NLR;LMR;IL-6;IL-8;OFS;OS;

Countries

China

Contacts

Public ContactLiu Jianhui

Tongji Hospital Affiliated to Tongji University

jianhuiliu_1246@163.com+86 13661452939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026